Evolvere BioSciences
London, United Kingdom· Est.
AI‑driven UK biotech accelerating discovery of novel oncology and immunology therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven UK biotech accelerating discovery of novel oncology and immunology therapeutics.
OncologyImmunology
Technology Platform
EvoML combines generative chemistry, predictive modeling, and automated synthesis planning to design and prioritize drug candidates across small molecules and biologics.
Opportunities
Strategic pharma collaborations and expansion into additional therapeutic areas could accelerate revenue generation and platform validation.
Risk Factors
Uncertainty in translating AI‑predicted molecules to clinical success and substantial capital requirements for IND‑enabling studies.
Competitive Landscape
Competes with AI‑driven discovery firms like Insilico, Exscientia, and Recursion; differentiation stems from its hybrid generative‑reinforcement learning approach and dual focus on small molecules and biologics.